Imagine a nephrologist with no biopsy needle, no imaging techniques,no serum creatinine measurement a nephrologist whosepatients need dialysis when they first present for care. Thisis the predicament of the diabetologist, whose patients withtype 1 diabetes routinely present with end-stage pancreaticbeta-cell failure and must be informed that they have an incurablecondition requiring lifelong rear-guard action against vascularcomplications. The future may not be so bleak, however. Thenatural history of the process leading to type 1 diabetes hasbeen charted by prospective studies; robust predictive strategiesare in place; and trials of a variety . . . [Full Text of this Article]
Schatz, D., Gale, E. A.M., Atkinson, M. A.
(2003). Why Can't We Prevent Type 1 Diabetes?: Maybe it's time to try a different combination. Diabetes Care
26: 3326-3328
[Full Text]
Killestein, J., Herold, K. C., Bluestone, J. A.
(2002). Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus. NEJM
347: 1116-1117
[Full Text]
(2002). New Approaches to Type 1 Diabetes: Some Promises, Some Failures. JWatch Pediatrics
2002: 1-1
[Full Text]